QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=AE4F7F7AAFC4068E9F3136CFBA2A254B;jsessionid=081E2E86E96080529C92C4FB5785CA02;jsessionid=9DEE06358B5105F91967B4C583C0631C;jsessionid=56858F1742CCF13F96D5F16484E7DBF7;jsessionid=F306762EEEC55EBB8E1988061017CBA3;jsessionid=F49800196439E4B1FC94169857DFAECB;jsessionid=5FF68B0F861EABA81AFDCD52AC1A6BD8 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. ATXN2 is a target of N-terminal proteolysis.
3. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…
4. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
5. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=AE4F7F7AAFC4068E9F3136CFBA2A254B;jsessionid=081E2E86E96080529C92C4FB5785CA02;jsessionid=9DEE06358B5105F91967B4C583C0631C;jsessionid=56858F1742CCF13F96D5F16484E7DBF7;jsessionid=F306762EEEC55EBB8E1988061017CBA3;jsessionid=F49800196439E4B1FC94169857DFAECB;jsessionid=5FF68B0F861EABA81AFDCD52AC1A6BD8